

Demyelinating Diseases

[View the current Demyelinating Diseases InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Demyelinating_Diseases.html) (PDF)
(http://www.bioportfolio.com/indepth/Demyelinating_Diseases.html) - Regularly Updated.

Recent Publications on Demyelinating Diseases:



- [Brainstem 1H nuclear magnetic resonance \(NMR\) spectroscopy: marker of demyelination and repair in spinal cord.](#)
Measuring in vivo spinal cord injury and repair remains elusive. Using... 18th November, 2009
Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN- *Ann Neurol.* 2009 Oct;66(4):559-64. ([DOI Direct Link](#))
- [Neuropathogenesis of Theiler's Murine Encephalomyelitis Virus Infection, An Animal Model for Multiple Sclerosis.](#)
Theiler's murine encephalomyelitis virus (TMEV) infection of mice is an... 7th November, 2009
Department of Pathology, University of Utah School of Medicine, 30 North- *J Neuroimmune Pharmacol.* 2009 Nov 6. ([DOI Direct Link](#))
- [Distinct subtypes of myelitis in systemic lupus erythematosus.](#)
OBJECTIVE: Myelitis causes pain, weakness, and sphincteric deficits, and... 31st October, 2009
The Johns Hopkins University, Baltimore, Maryland.- *Arthritis Rheum.* 2009 Nov;60(11):3378-87. ([DOI Direct Link](#))
- [Neurologic improvement after peripheral blood stem cell transplantation in poems.](#)
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid that mediates a... 31st October, 2009
- *Neurology.* 2009 Oct 6;73(14):1165; author reply 1165-6. ([DOI Direct Link](#))
- [Stuporous catatonia and white matter lesions.](#)
Axonal dysfunction as a result of persistent demyelination has been... 29th October, 2009
Department of Critical Care Medicine, Foothills Medical Centre,- *J Clin Neurosci.* 2009 Oct;16(10):1328, 1386.
- [Autoimmune diseases induced by biological agents A double-edged sword?](#)
Biological agents are increasingly used for a rapidly-expanding number of... 27th October, 2009
Laboratory of Autoimmune Diseases Josep Font, Institut d'Investigacions- *Autoimmun Rev.* 2009 Oct 23. ([DOI Direct Link](#))
- [In toxic demyelination oligodendroglial cell death occurs early and is FAS independent.](#)
Oligodendroglial cell death is a frequent phenomenon of many neurological... 27th October, 2009
Institute of Neuropathology, University Hospital Munster, Munster,- *Neurobiol Dis.* 2009 Oct 22. ([DOI Direct Link](#))
- [Revolutionary advances in the prevention of demyelinating diseases.](#)
This collective review focuses on three major factors that influence the... 27th October, 2009
Legacy Verified Level I Shock Trauma Center Pediatrics and Adults, Legacy- *J Environ Pathol Toxicol Oncol.* 2009;28(2):143-52.

- [Common CYP7A1 promoter polymorphism associated with risk of neuromyelitis optica.](#)
*Neuromyelitis optica (NMO) is a severe idiopathic inflammatory disease of...*24th October, 2009
Department of Neurology, National Cancer Center, 809 Madu 1-dong,- Neurobiol Dis. 2009 Oct 20. ([DOI Direct Link](#))
- [Molecular disruptions of the panglial syncytium block potassium siphoning and axonal saltatory conduction: pertinence to neuromyelitis optica and other demyelinating diseases of the central nervous system.](#)
*The panglial syncytium maintains ionic conditions required for normal...*24th October, 2009
Department of Biomedical Sciences, Program in Neuronal Growth and- Neuroscience. 2009 Oct 20. ([DOI Direct Link](#))
- [Demyelinating disease masquerading as a surgical problem: a case series.](#)
*INTRODUCTION: We report three cases of demyelinating disease with...*16th October, 2009
- J Med Case Reports. 2009 Aug 5;3:7407. ([DOI Direct Link](#))
- [\[Tumor-like inflammatory demyelinating diseases of the central nervous system with relapse onset: A case.\]](#)
*Here we report the clinical, radiological and neuropathological findings...*16th October, 2009
Department of Neurology, Peking University First Hospital, Beijing 100034,- Beijing Da Xue Xue Bao. 2009 Oct 18;41(5):588-9.
- [Sphingosine-1-phosphate and oligodendrocytes: From cell development to the treatment of multiple sclerosis.](#)
*Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid that mediates a...*8th October, 2009
Department of Biochemistry and Molecular Biology, Virginia Commonwealth- Prostaglandins Other Lipid Mediat. 2009 Apr 11. ([DOI Direct Link](#))
- [Evaluation of multiple sclerosis diagnostic criteria in Suzhou, China - risk of under-diagnosis in a low prevalence area.](#)
*Cheng X-J, Cheng Q, Xu L-Z, Zhao H-Q, Zhao Z, Wang W, Jiang G-X,...*7th October, 2009
Department of Neurology, Ruijin Hospital, Medical School of Shanghai Jiao- Acta Neurol Scand. 2009 Oct 5. ([DOI Direct Link](#))
- [Functional recovery of callosal axons following demyelination: a critical window.](#)
*Axonal dysfunction as a result of persistent demyelination has been...*6th October, 2009
Multiple Sclerosis Program, Department of Neurology, School of Medicine,- Neuroscience. 2009 Dec 29;164(4):1407-21. Epub 2009 Oct 2. ([DOI Direct Link](#))

Demyelinating Diseases Patents:



- 7560100- [Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases](#)
- 7576090- [Benzazole analogues and uses thereof](#)
- 7576101- [Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents](#)
- 7576106- [Piperidine derivatives and methods of use](#)
- 7576109- [1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof](#)
- 7576182- [Compositions and methods for the treatment of immune related diseases](#)
- 7576211- [Synthesis of thienopyridinone compounds and related intermediates](#)

- [7576218- 4-phenylpiperidine-pyrazole CCR1 antagonists](#)
- [7579188- Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury](#)
- [7579328- DNA vaccination for treatment of multiple sclerosis and insulin-dependent diabetes mellitus](#)
- [7582603- Method for treating or inhibiting intestinal inflammation](#)
- [7575745- Ligand for herpes simplex virus entry mediator and methods of use](#)
- [7572819- Compounds which potentiate glutamate receptor and uses thereof in medicine](#)
- [7572812- Therapeutic agents useful for treating pain](#)
- [7560108- Anti-TNF.alpha. antibodies](#)
- [7560112- Anti-il-6 antibodies, compositions, methods and uses](#)
- [7560247- Nucleic acids encoding anti-IL-12 antibodies, and methods of production](#)
- [7560449- Methods and therapeutic combinations for the treatment of demyelination](#)
- [7563811- 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof](#)
- [7563862- Neural regeneration peptides and methods for their use in treatment of brain damage](#)
- [7566735- Compounds which potentiate AMPA receptor and uses thereof in medicine](#)
- [7569384- Albumin fusion proteins](#)
- [7569544- Methods of increasing delivery of active agents to brain comprising administering receptor associated protein \(RAP\) fragments conjugated to active agents](#)
- [7569568- Cytokine inhibitors](#)
- [7582635- Therapeutic agents useful for treating pain](#)
- [7585838- Methods of treating fibromyalgia caused by small intestinal bacterial overgrowth](#)
- [7608406- Diagnostic markers of stroke and cerebral injury and methods of use thereof](#)
- [7608704- Secreted proteins](#)
- [7611879- 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)
- [7612060- Triazoles and methods of use](#)
- [7612078- Piperidinylamino-thieno\[2,3-D\] pyrimidine compounds](#)
- [7612104- Bicyclic aryl-sulfonic acid \[1,3,4\]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use](#)
- [7612181- Dual variable domain immunoglobulin and uses thereof](#)
- [7612226- Amino acid derivatives](#)
- [7615359- Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use](#)
- [7615552- Fused heterocyclic compounds](#)
- [7605240- Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth](#)
- [7605229- PRO87299 polypeptides](#)
- [7605120- Antagonists of the bradykinin B1 receptor](#)
- [7589199- Substituted piperazines](#)
- [7592010- Albumin fusion proteins](#)
- [7592332- Cytokine inhibitors](#)
- [7592449- Structural carotenoid analogs for the inhibition and amelioration of disease](#)
- [7598259- mGluR1 antagonists as therapeutic agents](#)
- [7598266- Fused heterocyclic derivatives as PPAR modulators](#)
- [7601335- Pretreatment of a biological sample from an autoimmune disease subject](#)
- [7601514- Nucleic acid encoding PRO10268 polypeptides](#)
- [7601745- Heterocyclic NF-kB inhibitors](#)
- [7601818- Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors](#)
- [7618969- Compounds which potentiate glutamate receptor and uses thereof in medicine](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

